Actinogen Medical Limited (FRA:3AC)
Germany
· Delayed Price · Currency is EUR 0.0295
+0.0005 (1.72%)
Last updated: Dec 5, 2025, 8:03 AM CET
Actinogen Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| Other Revenue | 5.49 | 9.93 | 4.89 | 3.64 | 1.98 | Upgrade
|
| Revenue | 5.49 | 9.93 | 4.89 | 3.64 | 1.98 | Upgrade
|
| Revenue Growth (YoY) | -44.73% | 103.18% | 34.28% | 83.47% | -43.58% | Upgrade
|
| Gross Profit | 5.49 | 9.93 | 4.89 | 3.64 | 1.98 | Upgrade
|
| Selling, General & Admin | 6.46 | 5.93 | 5.05 | 3.27 | 2.82 | Upgrade
|
| Research & Development | 12.3 | 15.54 | 8.9 | 8.21 | 2.41 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 | Upgrade
|
| Operating Expenses | 20.84 | 23.19 | 15.87 | 13.17 | 5.9 | Upgrade
|
| Operating Income | -15.35 | -13.26 | -10.99 | -9.53 | -3.92 | Upgrade
|
| Interest Expense | -0.05 | -0.02 | -0.02 | -0.02 | -0.02 | Upgrade
|
| Interest & Investment Income | 0.69 | 0.29 | 0.37 | 0.04 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.06 | -0.12 | 0.01 | - | Upgrade
|
| EBT Excluding Unusual Items | -14.73 | -13.04 | -10.75 | -9.5 | -3.92 | Upgrade
|
| Pretax Income | -14.73 | -13.04 | -10.75 | -9.5 | -3.92 | Upgrade
|
| Net Income | -14.73 | -13.04 | -10.75 | -9.5 | -3.92 | Upgrade
|
| Net Income to Common | -14.73 | -13.04 | -10.75 | -9.5 | -3.92 | Upgrade
|
| Shares Outstanding (Basic) | 2,980 | 2,174 | 1,802 | 1,717 | 1,405 | Upgrade
|
| Shares Outstanding (Diluted) | 2,980 | 2,174 | 1,802 | 1,717 | 1,405 | Upgrade
|
| Shares Change (YoY) | 37.04% | 20.69% | 4.92% | 22.20% | 25.69% | Upgrade
|
| EPS (Basic) | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | Upgrade
|
| Free Cash Flow | -7.59 | -16.96 | -8.73 | -9.52 | -1.73 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -279.70% | -133.47% | -224.74% | -261.90% | -197.56% | Upgrade
|
| Profit Margin | -268.37% | -131.34% | -219.98% | -260.91% | -197.32% | Upgrade
|
| Free Cash Flow Margin | -138.33% | -170.76% | -178.70% | -261.53% | -87.20% | Upgrade
|
| EBITDA | -15.01 | -12.92 | -10.66 | -9.21 | -3.6 | Upgrade
|
| EBITDA Margin | -273.48% | -130.10% | -218.10% | -253.12% | -181.39% | Upgrade
|
| D&A For EBITDA | 0.34 | 0.33 | 0.32 | 0.32 | 0.32 | Upgrade
|
| EBIT | -15.35 | -13.26 | -10.99 | -9.53 | -3.92 | Upgrade
|
| EBIT Margin | -279.70% | -133.47% | -224.74% | -261.90% | -197.56% | Upgrade
|
| Revenue as Reported | 6.17 | 10.22 | 5.25 | 3.68 | 2.01 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.